Publication Title
Kidney Int Rep
Document Type
Article
Publication Date
2-1-2019
Keywords
chronic hepatitis C; chronic kidney disease; direct-acting antiviral; hepatitis C virus
Abstract
Introduction: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment.
Methods: We performed a
Results: SVR12 rates in patients with stage 1, 2, and 3 CKD were 97% (439/453), 98% (536/547), and 97% (32/33), respectively, with OBV/PTV/r + DSV; and, 96% (1172/1221), 96% (1208/1254), and 93% (55/59), respectively, with OBV/PTV/r + DSV + RBV. Overall rates of serious AEs and renal AEs were 3% (95/3567) and 2% (56/3567), respectively. Factors associated with an eGFR increase of ≥10 ml/min per 1.73 m
Conclusion: OBV/PTV/r + DSV ± RBV achieved high SVR rates and was generally well tolerated irrespective of CKD stage.
Clinical Institute
Kidney & Diabetes
Specialty/Research Institute
Nephrology
